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Abstract
Background: It has been demonstrated that acute GPLC supplementation produces enhanced anaerobic work
capacity with reduced lactate production in resistance trained males. However, it is not known what effects chronic
GPLC supplementation has on anaerobic performances or lactate clearance.
Purpose: The purpose of this study was to examine the long-term effects of different dosages of GPLC
supplementation on repeated high intensity stationary cycle sprint performance.
Methods: Forty-five resistance trained men participated in a double-blind, controlled research study. All subjects
completed two testing sessions, seven days apart, 90 minutes following oral ingestion of either 4.5 grams GPLC or
4.5 grams cellulose (PL), in randomized order. The exercise testing protocol consisted of five 10-second Wingate
cycle sprints separated by 1-minute active recovery periods. Following completion of the second test session, the
45 subjects were randomly assigned to receive 1.5 g, 3.0 g, or 4.5 g GPLC per day for a 28 day period. Subjects
completed a third test session following the four weeks of GPLC supplementation using the same testing protocol.
Values of peak power (PP), mean power (MP) and percent decrement of power (DEC) were determined per bout
and standardized relative to body mass. Heart rate (HR) and blood lactate (LAC) were measured prior to, during
and following the five sprint bouts.
Results: There were no significant effects of condition or significant interaction effects detected for PP and MP.
However, results indicated that sprint bouts three, four and five produced 2 - 5% lower values of PP and 3 - 7%
lower values of MP with GPLC at 3.0 or 4.5 g per day as compared to baseline values. Conversely, 1.5 g GPLC
produced 3 - 6% higher values of PP and 2 -5% higher values of MP compared with PL baseline values. Values of
DEC were significantly greater (15-20%) greater across the five sprint bouts with 3.0 g or 4.5 g GPLC, but the 1.5 g
GPLC supplementation produced DEC values -5%, -3%, +4%, +5%, and +2% different from the baseline PL values.
The 1.5 g group displayed a statistically significant 24% reduction in net lactate accumulation per unit power
output (p < 0.05).
Conclusions: The effects of GPLC supplementation on anaerobic work capacity and lactate accumulation appear
to be dosage dependent. Four weeks of GPLC supplementation at 3.0 and 4.5 g/day resulted in reduced mean
values of power output with greater rates of DEC compared with baseline while 1.5 g/day produced higher mean
values of MP and PP with modest increases of DEC. Supplementation of 1.5 g/day also produced a significantly
lower rate of lactate accumulation per unit power output compared with 3.0 and 4.5 g/day. In conclusion, GPLC
appears to be a useful dietary supplement to enhance anaerobic work capacity and potentially sport performance,
but apparently the dosage must be determined specific to the intensity and duration of exercise.
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Exercise capacity is generally considered as the greatest
amount of physical exertion that can be sustained at a
given level of intensity. Success in endurance sports is
related to an ability to continue with relatively high
efforts for extended periods of time. In contrast, most
team sports involve intermittent bouts of high intensity
exertion with limited recovery intervals. A number of
strategies are commonly utilized to increase exercise
capacity as a means of enhancing sport performance.
These include various approaches to training and condi-
tioning as well as nutritional strategies to improve peak
exercise capacity as well as exercise efficiency.
While numerous factors underlie exercise capacity, a
primary consideration is that of energy demand versus
energy supply. The intensity of exercise corresponds- to
a great degree- to the specific energy demands of the
activity. The capacity to perform at a given intensity of
effort is limited by the localized energy supplies and the
ability to replenish those energy stores as exercise con-
tinues. In conjunction with the increased metabolic
demand for energy during exercise, there is increased
blood flow to the exercising muscles [1]. During exercise,
the vasculature system is the sole means to deliver energy
replenishment as well as to remove metabolites that may
limit ongoing efforts. A close pairing of exercise intensity
and local blood flow suggests that potential strategies
capable of increasing blood flow to exercising muscles
may enhance maximal work capacity and/or increase
resistance to localized muscle fatigue during ongoing
exercise at submaximal intensities.
The process of increasing blood flow to exercising mus-
culature involves shunting of blood from non-active tis-
sues to working muscle. As physical exercise increases in
intensity, there are a number of mechanisms involved in
the vasodilation of the arterioles and the pre-capillary
sphincters [2]. These vasodilatory mechanisms are diverse
but share two distinct characteristics in that the activity of
each of the differing mechanisms increases in direct
response to increasing intensities of exercise and those
mechanisms all initiate the synthesis of nitric oxide (NO).
Nitric oxide is the endothelial factor responsible for
relaxation of smooth musculature surrounding the arter-
ials and the pre-capillary sphincters thereby producing
vasodilation and increased blood flow into the capillary
bed of the exercising muscle tissue. Since its identification
approximately twenty years ago, various research studies
and subsequent sports nutrition products have emerged in
an effort to manipulate levels of NO in order to enhance
exercise performance. This quest has resulted in a sizable
nutritional supplement market, primarily composed of
arginine based products. While arginine is the precursor
of NO, there is no scientific evidence to support such an
approach. In fact, all published studies in this area indicate
that oral administration of arginine in dosages tolerated by
the gastrointestinal system are not effective in producing
endothelium-dependent vasodilation or in elevating NO
levels [3-5].
It has been demonstrated that short term administra-
tion of an oral carnitine compound, glycine propionyl-
L-carnitine (GPLC), produces significantly elevated
levels of nitric oxide metabolites at rest in both seden-
tary and trained persons [6,7]. Increased nitric oxide
activity has also been demonstrated in resistance trained
persons with reactive hyperaemia testing, an assessment
used in clinical settings that, to some degree, simulates
the physical stresses encountered during very intense
exercise such as resistance training [7]. These studies
are the first to document the effectiveness of an oral
nutritional supplement to directly affect NO synthesis.
It has also been recently shown that acute GPLC sup-
plementation (4.5 g) enhances anaerobic work capacity
with reduced lactate production in resistance trained
males [8]. However, little is known regarding the effects
chronic GPLC supplementation has on exercise perfor-
mance in trained persons. It was the purpose of the pre-
sent investigation to examine the effects of 28 days of




Forty-five male resistance trained individuals volun-
teered to participate in this double-blind investigation.
Study inclusion criteria limited research subjects to
males between the ages of 18 and 35 years, who
reported participation in at least two weekly resistance
training sessions over the six-month period immediately
prior to the start of the study. Exclusionary criteria
included any reported history of significant cardiore-
spiratory complications or recent lower extremity mus-
culoskeletal injury that might limit high intensity
exercise efforts. Subjects provided written informed con-
sent after verbal explanation of all study procedures, in
accordance with the Institutional Medical Sciences Sub-
committee for the Protection of Human Subjects.
Study Design
All subjects were asked to complete three testing ses-
sions. The first two test sessions were performed one
week apart with the third trial scheduled 28 days later.
The first two tests were performed 90 minutes following
oral ingestion of either 4.5 grams GPLC or 4.5 grams
cellulose (PL), in randomized order. The exercise testing
protocol consisted of five 10-second Wingate cycle
sprints separated by 1-minute active recovery periods.
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publication, reported significantly increased power out-
put with reduced lactate accumulations with acute
GPLC supplementation (Jacobs, 2009).
The present investigation is a continuation of our acute
study of GPLC in which a randomized blocks design was
implemented to examine the long-term effects of varying
dosages of GPLC. All of the present subjects completed
acute testing with GPLC and PL in order to provide a
consistent subject test exposure for the present investiga-
tion. The PL condition served as the control/baseline
condition for the present study. Pilot testing had indi-
cated that the majority of persons could correctly identify
to GPLC condition compared with placebo. As it is well
established that subject compliance and retention are sig-
nificantly reduced when a placebo condition is identified,
the present design was utilized in which the placebo con-
dition of the first two assessments served as the baseline
condition, each subject serving as their own control. Sub-
jects were matched by body mass and then randomly
a s s i g n e dt oo n eo ft h r e es t u d yg r o u p s ,w i t ho n eg r o u p
receiving 1.5 grams per day of GPLC, one group receiving
3.0 grams GPLC per day, and the final group receiving a
daily dosage of 4.5 grams of GPLC. (See Supplementation
Protocol Section).
During the one month supplementation period, sub-
jects were directed to continue with their own individual
training and nutritional programs. Seven day exercise
logs and three day dietary recall logs were completed by
all subjects to provide verification of the consistency of
training and diet. These exercise and dietary records
were submitted for the weeks prior to baseline and post
supplementation testing. The exercise logs provided
information regarding exercise volume (sets, reps) of
resistance training categorized to upper extremity, lower
extremity, or structural movements. The dietary intake
logs were examined using ESHA Food Processor SQL
dietary analysis software (ESHA Research, Salem, OR).
All subjects were scheduled for a third cycle sprint
session following the 28 days of supplementation. As
with the prior assessments, subjects were asked to
report for testing in the morning following 12 hr with-
out food and to not participate in heavy exercise during
the 24 hr period before testing. On test day, the subjects
were provided with the same dosing as they had taken
during the 28 day supplementation period. All subjects
sat quietly for 90 minutes after taking the supplement
before participating in the cycle sprint testing.
Supplementation Protocol
Subjects were matched by body mass and then ran-
domly assigned to one of three study groups, each
group receiving 28 days of GPLC supplementation in
one of three dosages (1.5 g/d, 3.0 g/d, 4.5 g/d). In a
double blind fashion, each subject was provided with 28
packets consisting of six capsules per day. The daily
packets included six 750 mg capsules provided by Jar-
row Formulas (Los Angeles, CA). The respective daily
dosage was established by the appropriate combination
of 750 mg GPLC capsules and 750 mg capsules of cellu-
lose (the GPLC and cellulose capsules were visually
identical). For example, the daily packets of the 1.5 g/d
group were comprised of two GPLC capsules and four
cellulose capsules while the 3.0 g/d group received four
GPLC and two cellulose capsules and the 4.5 g/d group
was provided with six GPLC capsules. Participants were
directed to take their six capsule daily supplements
approximately 90 minutes prior to exercise on training
days and to take the six capsules with breakfast on
other days. The GPLC used in this study was the USP
grade nutritional product, GlycoCarn™ (Sigma Ta Health
Sciences, S.p.A., Rome, Italy), a molecularly bonded
form of glycine and propionyl-L-carnitine.
Assessment Protocol
The testing protocol used in the present investigation is
consistent with that previously described by these inves-
tigators (Jacobs, 2009). Briefly, this testing protocol
included five high intensity stationary cycle sprints, each
sprint 10-seconds in duration with 1-minute active
recovery periods. Sprints were performed with a Mon-
arch 894E leg ergometer (Monarch, Varberb, Sweden)
with the external applied resistance equivalent to 7.5%
of each subject’s body mass. Ten minutes of unloaded
pedalling at 60 RPM was performed as a warm-up prior
to the sprint testing. The 1-minute recovery periods
were active with unloaded pedalling with cadence fixed
at 60 RPM.
Anaerobic power output was measured using the
SMI OptoSensor 2000 (Sports Medicine Industries, Inc.,
St. Cloud, Minn). Power output variables included peak
power (PP) which was determined as the power output
established during the first 5 seconds of each ten second
sprint; and mean power (MP) which was the power out-
put measured during the full ten seconds of each sprint.
The third power output variable was a power decrement
(DEC) which was calculated as the difference in power
output between the first 5 seconds and the second five
seconds of each sprint, as expressed as a percentage of
the first 5 second period.
Heart rate (HR) was determined using a Polar HR
monitoring system with HR values assessed at rest, dur-
ing the final five seconds of each sprint bout, as well as
four and fourteen minutes after the final sprint bout.
Blood lactate levels (LAC) were assessed using the
Accutrend® lactate analyzer (Sports Resource Group,
Inc., Pleasantville, NY). Calibration procedures were per-
formed prior to each testing session using standard
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at rest as well as four and fourteen minutes post exer-
cise. Net lactate accumulation per unit power output
was calculated as (LAC14-LACrest)·(MPave)
-1.
Thigh girth of the dominant leg was measured using
a Gulick tape at 15 mm superior to the patella while in
a standing position with weight shifted onto the non-
dominant leg. Thigh girth measurements were taken at
rest and four minutes after the final sprint bout.
Statistical Analyses
A repeated measures general linear model was used to
examine for differences in outcome measures between
groups (1.5 g/d, 1 g/d, 4.5 g/d), conditions (pre- and
post-GPLC) and across time. Measures of power output
(PP, MP, DEC) were determined across time during each
of the five successive sprint bouts. Values of HR were
established at rest, during the final five seconds of each
sprint, as well as four and fourteen minutes following the
last sprint. The across time measures of LAC were taken
at rest as well as four and fourteen minutes post exercise
while thigh girth was assessed at rest and four minutes
after the fifth sprint. In cases where significant main
effects or interactions were observed, single degree of
free contrasts were performed to determine specific
effects without adjustment of the acceptable level of sig-
nificance. Net lactate accumulation was calculated as the
difference between lactate measurements 14 min post
exercise and resting values divided by the average MP
values of the five sprints. In all cases, p-values less than
0.05 were accepted to determine statistical significance.
All analyses were performed using PASW, Version 17.
Results
Research Participants
Of the 45 participants enrolled for this study, 38 indivi-
duals completed all study assessments. All statistical
analyses were based on the data derived from partici-
pants who completed all requisite testing sessions. The
total subject pool consisted of 13 subjects from the 1.5
g/d group, 11 subjects from the 3.0 g/d group and 14
subjects from the 4.5 g/d group, respectively. The seven
participants who did not complete the study testing
included three individuals that developed musculoskele-
tal injuries from other activities (intramural sports), two
that did not maintain consistent levels of exercise train-
ing, and two that declined to participate in the final
sprint testing session. Subject demographics are pro-
vided by group in Table 1. There were no significant
differences between groups in demographic factors.
Dietary Log Data
Table 2 provides macronutrient intake values of each of
the three supplementation groups, for the one-week
period prior to initial and post-treatment testing. Ana-
lyses indicated that there were no significant differences
between groups at baseline or at post-testing in the diet-
ary intake of carbohydrates, fats, or protein or in the
values of total calories ingested. Nor were there any sig-
nificant differences detected within groups between the
initial and post-treatment assessments.
Exercise Log Data
Participants were asked to complete a log of all resis-
tance training exercise performed during the week prior
to initial testing and last week of the four week study.
These logs included the number of sets per exercise,
with exercises classified by investigators as either upper
or lower extremity and also as either single-joint or
multi-joint movements. The training volume values are
presented in Table 3. Analyses revealed no significant
differences between study groups in the number of sets
or repetitions regardless of exercise categories.
Power Output
Analyses indicated statistically significant main effects
for time (bout order) for PP, MP, and DEC (p’s<
0.001). In general, values of PP and MP tended to
decrease in value with ongoing sprint bouts while DEC
tended to increase. There were no significant differences
detected among the three study groups (1.5 g/d, 3.0 g/d,
4.5 g/d) in baseline power values.
Peak Power
Changes in PP from baseline with supplementation
across the five sprints are graphically presented in
Figure 1. Values of PP were 4.7%, 1.6%, 3.3%, 5.1%, and
6.8% higher with the 1.5 g/d dosage compared with
baseline values. Conversely, the 3.0 g/d group displayed
4.3% and 6.0% lower values of PP with the 4
th and 5
th
sprint and the PP was up to 4.7% lower with the 4.5 g/d
dosage. Despite the differences between mean group PP
values, there were no statistically significant main effects
of GPLC or interactions.
Mean Power
Figure 2 provides a visual depiction of the mean changes
in MP with treatment for the three groups. The 3.0 g/d
group produced considerably less MP on all five sprints
(-1.5%, - 7.6%, -9.0%, -7.0, -3.3) and the 4.5 g/d group
had lower values of MP on sprints two through five
(-2.5%, -3.6%, -6.9%, -1.1). In contrast, greater MP was
reached on all bouts with the 1.5 g/d dosage with gains
Table 1 Subject Demographics
1.5 g/d 3.0 g/d 4.5 g/d
Age (yrs) 25.5 ± 6.4 24.8 ± 4.9 23.6 ± 3.4
Body Mass (kg) 89.6 ± 14.3 84.2 ± 11.2 84.3 ± 17.2
Height (cm) 179.0 ± 4.4 178.7 ± 7.6 173.5 ± 5.7
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and +5.1% compared with baseline. No statistically sig-
nificant effects of treatment or factor interactions were
detected.
Power Decrement
In addition to the significant effect of time previously
mentioned, DEC values were also observed to be signifi-
cantly affected by condition (pre- and post-GPLC) and
by a condition x group interaction (p < 0.05). These sta-
tistics suggest that the rate of power decrement across
the five sprint bouts changed from baseline differentially
among the three supplement levels. Figure 3 provides an
illustration of the contrasting changes in DEC between
groups. Values of DEC were appreciably greater with
the 3.0 g/d dosage (+19.1%, +9.1%, +19.4%, +10.7%,
+19.3%) and with the 4.5 d/g intake (+17.6%, +19.0%,
+16.0%, +19.3%, + 11.8%). The 1.5 g/d group displayed
lower values of DEC on the first two sprints (-5.2%,
-3.22%) with DEC on sprints three through five 2 - 5%
higher than initial values. In general, the 3.0 and 4.5 g/d
groups exhibited dramatically greater rates of DEC com-
pared with baseline while the 1.5 g/d dosage resulted in
greater resistance to fatigue on sprints 1 and 2 with
more modest changes in DEC with sprints 3 -5.
Lactate
Lactate values at baseline, 4 and 14 min post exercise in
each of the three supplementation groups are provided
in Table 4. LAC values were significantly different
across time in all groups (p < 0.05) with greater values
post-exercise (4 and 14 min) compared with baseline
values. The general pattern of reduced lactate accumula-
tion with GPLC is apparent to some degree in the three
study groups, but only the 1.5 g/d group displayed a
strong trend (p = 0.07) for statistically significant reduc-
tion in absolute blood lactate levels at 14 min post
sprints. Net lactate accumulation per unit power output
was calculated as (LAC14-LACrest)·(MPave)
-1 with values
only differing with GPLC in the 1.5 g/d group. The 1.5
g/d GPLC supplementation group exhibited a 24.1%
reduction in net lactate per watt (1.44 to 1.09 mmol
.watt
-
1) (p < 0.05). The 3.0 g/d group actually produced 27.0%
more lactate per unit watt (.80 to 1.02 mmol
.watt
-1)a n d
the 4.5 g/d group displayed a non-significant 11.6%
reduction (1.24 to 1.09 mmol
.watt
-1) .T h ec h a n g ei nn e t
lactate accumulation per unit power output of the 1.5 g/d
group was significantly greater than the changes exhib-
ited by the other two groups (p < 0.05).
Heart Rate
There were no significant main effects or significant
interactions detected in values of HR at rest, during or
following the five sprints. The mean HR responses were
similar in the three study groups at rest (approximately
61-63 bpm) and in response to the sprint bouts with
mean HRs increasing from 150-155 bpm to approxi-
mately 170 bpm from the first to fifth sprint bout.
Recovery HR values did not differ appreciably between
Table 2 Nutritional Recall Information
1.5 g/d 3.0 g/d 4.5 g/d
Carbohydrates (g) Baseline 210.3 ± 91.5 254.5 ± 149.5 238.2 ± 115.1
4 weeks 257.0 ± 143.6 254.4 ± 162.2 242.1 ± 117.9
Fats (g) Baseline 76.5 ± 24.2 62.1 ± 25.2 76.5 ± 38.4
4 weeks 58.0 ± 16.4 65.0 ± 29.2 73.4 ± 43.1
Protein (g) Baseline 190.3 ± 82.6 178.3 ± 92.5 165.8 ± 76.4
4 weeks 197.6 ± 76.0 163.1 ± 109.5 178.4 ± 78.6
Total Calories (kcal/day) Baseline 2322.1 ± 528.0 2229.5 ± 717.2 2317.8 ± 661.2
4 weeks 2264.9 ± 574.1 2160.8 ± 901.1 2418.2 ± 760.3
Table 3 Resistance Training Log Data
1.5 g/d 3.0 g/d 4.5 g/d
Baseline 4 weeks Baseline 4 weeks Baseline 4 weeks
Upper Extremity Compound Exercises Sets 40.6 ± 16.8 39.7 ± 19.3 40.8 ± 16.1 46.0 ± 24.6 42.8 ± 21.1 34.4 ± 15.0
Reps 469.3 ± 347.1 379.2 ± 191.7 398.9 ± 204.1 413.2 ± 189.1 521.9 ± 421 341.8 ± 210.5
Upper Extremity Single Joint Exercises Sets 35.9 ± 19.1 35.5 ± 25.9 34.5 ± 23.1 33.8 ± 22.3 42.0 ± 22.8 41.2 ± 30.5
Reps 453.8 ± 287.4 391.2 ± 352.5 380.8 ± 281.4 333.9 ± 192.6 541.4 ± 308.1 448.2 ± 429.4
Lower Extremity Compound Exercises Sets 9.3 ± 7.8 13.9 ± 12.7 10.7 ± 9.2 14.6 ± 17.7 7.2 ± 6.3 12.9 ± 8.1
Reps 106.8 ± 135.5 141.0 ± 168.8 113.0 ± 103.3 153.7 ± 316.7 89.7 ± 153.0 113.9 ± 81.1
Lower Extremity Single Joint Exercises Sets 8.2 ± 8.6 6.9 ± 6.8 8.2 ± 7.5 7.4 ± 4.4 8.4 ± 9.5 7.4 ± 8.1
Reps 131.7 ± 251.0 73.4 ± 73.2 93.7 ± 88.4 82.1 ± 67.5 153.6 ± 316.8 67.1 ± 78.3
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four and 14 minutes following sprinting, respectively.
Thigh Girth
Analyses revealed no significant effects of GPLC in any
dosage or interactions in regard to thigh circumferential
measurements. There was a significant time effect as the
post-exercise assessment produced greater thigh girth
measurements with exercise across all study participants.
However, while there were no statistically significant
interaction effects with the supplementation level
(groups) it is interesting to note that while the 3.0 and
4.5 g/d groups displayed similar increases in mean thigh
girth with treatment (3.0 g/d: 1.7 to 2.2 cm; 4.5 g/d: 1.7
to 2.0 cm) the 1.5 g/d study group displayed acute
increases of thigh girth of 1.3 cm both at baseline test-
ing and after four-weeks of supplementation.
Discussion
Findings of the present investigation suggest that increas-
ing daily intake of GPLC has somewhat paradoxical influ-
ences on the performance of repeated high intensity cycle
sprints. These authors have previously reported that
GPLC may produce acute enhancement of anaerobic
power output during repeated cycle sprints [8]. Based on
those results, it was speculated that long-term supple-
mentation would, in general, provide further perfor-
mance enhancements with those improvements related
directly to the greater duration of supplementation and
to the daily GPLC intake. However, these current find-
ings indicate that long-term GPLC supplementation at
the higher dosages examined (3.0 and 4.5 g/d) did not
result in greater values of power output but rather lower
mean values of PP and MP. In contrast, the lower intake
group (1.5 g/d) exhibited mean values of PP and MP
greater than baseline across the five sprints. Those
increases in power output were similar to those pre-
viously reported with acute intake of 4.5 g GPLC.
The results of this study are not sufficient to defini-
tively explain the apparent decline in sprint performance
with higher GPLC intake. However, examination of the
mechanisms of action may allow useful supposition.
Potential mechanisms involved in the observed acute per-
formance improvements include the unique vasodilatory
Figure 1 Percent change of Peak Power (PP) from baseline
determined during repeated cycling sprints in the 1.5 g/d
group (black columns), in the 3.0 g/d group (gray columns)
and in the 4.5 g/d group (white columns).
Figure 2 Percent change of Mean Power (MP) from baseline
determined during repeated cycling sprints in the 1.5 g/d
group (black columns), in the 3.0 g/d group (gray columns)
and in the 4.5 g/d group (white columns).
Table 4 Lactate Measurements (mmol · L
-1)
Resting 4-min post 14- min post
1.5 g/d Baseline 1.3 ± 0.4 11.3 ± 4.0 11.8 ± 2.5
4 weeks 1.5 ± 0.4 11.0 ± 3.3 9.4 ± 4.4
3.0 g/d Baseline 1.8 ± 0.7 11.6 ± 3.4 8.2 ± 3.0
4 weeks 1.6 ± 0.4 10.5 ± 4.4 9.4 ± 4.1
4.5 g/d Baseline 1.8 ± 0.4 12.2 ± 3.0 11.9 ± 4.2
4 weeks 1.6 ± 0.6 11.5 ± 3.7 9.6 ± 3.6
Figure 3 Percent change in the decrement in power output
(DEC) from baseline determined during repeated cycling
sprints in the 1.5 g/d group (black columns), in the 3.0 g/d
group (gray columns) and in the 4.5 g/d group (white
columns).
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the form of the propionyl group. An increased cellular
supply of carnitine may also provide anaerobic buffering
thereby reducing lactate production and enabling greater
resistance to fatigue with high intensity exercise. It is
likely that blood serum and tissue concentration levels of
carnitine and propionate increase over time to some
point of saturation. It is recommended that future inves-
tigations examine the time by dosage dynamics involved
in GPLC supplementation.
The mechanisms involved in acute enhancement of
power output and reduced lactate accumulation are possi-
bly (in higher intake levels) also responsible for the
reduced mean values of power seen with long-term intake.
These authors suggest that it is unlikely that greater levels
of propionate or carnitine in the blood stream or muscle
tissue would reduce the production of power during the
repeated sprints. However, it appears quite probable that
the vasodilatory effects of GPLC surpassed a beneficial
magnitude in the 3.0 and 4.5 g/d groups. A post-hoc
examination of participant statements regarding their con-
dition following the final testing session revealed that 13
of the 38 individuals completing the study complained
that discomfort associated with leg pump limited their
sprinting performance. These 13 included five of the 12
individuals in the 3.0 g/d group, and seven of the 14 parti-
cipants in the 4.5 g/d group but only one individual in the
1.5 g/d group reported leg pump as a limiting factor.
While not statistically significant, the 3.0 and 4.5 g/d
groups displayed greater mean increases in thigh girth
with sprinting compared with baseline while the 1.5 g/d
group exhibited the same relative leg pump. Thus, while
the results of this study cannot definitively explain the lack
of power output enhancement with long-term intake of
GPLC, the limited information available suggests that
excessive localized muscle pumping is involved.
With increasing intensity of exercise, there is propor-
tional increase in local blood flow of the exercising mus-
culature. Vasodilation provides up to 25 -50 times resting
levels of local blood flow by means of relaxation of the
smooth arterial musculature and of the sphincter allow-
ing flow into the capillary bed [9]. The process of vasodi-
lation is closely associated with NO as this short-lived,
reactive nitrogen molecule is responsible for regulation
of vascular muscle tone [10]. Since it was determined
that NO has a vital role in the control of blood flow,
scientists have speculated on the effects increased levels
would have on cardiovascular functioning in particular
and exercise performances in general. However, this
question has remained a matter of supposition as no
nutritional supplementation has proven capable of influ-
encing NO synthesis, until recently.
The only food supplement shown to directly affect the
production of NO is GPLC. It has been shown that 28 d
GPLC at 4.5 g/d produces significantly elevated levels
of nitrites and nitrates [6,7]. Acute supplementation at
4.5 g resulted in significant improvements in cycling
power output [8], but in the current study long-term
supplementation of GPLC at that daily intake was not
associated with power enhancement. Rather after 28 d
GPLC at 4.5 g/d there was a significantly greater rate of
power decline within individual sprints with reduced
mean power output. In contrast, 28 d at a lower dosage,
1.5 g/d, provided increased mean values of power similar
to those exhibited acutely with 4.5 g. The increases in
NO reported after 28 d GPLC at 4.5 g/d are apparently
associated with the extreme leg pump that limited cycling
power in the present study. Similarly, with 4.5 g/d there
was a significant reduction in net lactate accumulation
per unit power acutely - with like reductions also
observed after 28 d at 1.5 g/d, but not but not after 28 d
at 4.5 g/d. Apparently, the long-term effects of GPLC are
related to the timed effects of different individual
mechanisms. The vasodilatory effects are certainly
directly related to NO levels while the increased power
output may be related to increased cellular supply of the
propionate unit which when converted to succinate pro-
vides an anaplerotic energy substrate. Greater carnitine
supply may be responsible for the reduced lactate accu-
mulation due to buffering of the Coenzyme A pool
thereby reducing the rate of fatigue and enabling a higher
rate of power output. It would appear that both the vaso-
dilatory effects and power output enhancement effects
increased in magnitude over the 28 d period of the pre-
sent study.
The present study is limited by several factors includ-
ing a modest sample size which restricted the statistical
analyses. Some variability within groups could be asso-
ciated with the lack of control of the study supplement.
Study participants were provide with 28 days of GPLC
in the respective group levels and directed to take six
capsules daily. However, there were no means available
to ensure daily intake of the respective supplements.
This investigation applied three absolute dosage levels
(1.5, 3.0, 4.5 g/d) in all research participants. The abso-
lute dosing regardless of body mass likely increased the
variability of response within supplementation groups
thereby limiting the findings of the present study. It is
recommended that future investigations examine GPLC
dosing relative to body mass.
Regardless of these potential limitations, the total sub-
ject pool in this study did not display the same main
effects for enhancement of power output with reduced
lactate accumulation as had been observed with acute
supplementation. While the lower intake group (1.5 g/d)
did display improvements in mean values of power out-
put with significantly lower net lactate accumulation per
unit power output, the higher intake groups (3.0 and
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output. From the participant reports and the relatively
crude thigh girth measurements, it would appear that
the higher intake levels produced greater levels of leg
pump which acted as a hindrance during high speed,
high intensity cycle sprints. However, this is not to
imply that the higher intake levels would be disadvanta-
geous in all sports situations and could possibly prove
to be beneficial in some particular settings. Significant
increases of blood flow to exercising muscles may pro-
vide training benefits for some athletes during certain
types of competition or physical conditioning. For exam-
ple, the high degree of leg pump might provide unique
athletic conditioning benefits to those in the competitive
bodybuilding field and others during particular phases
of training.
Conclusion
Chronic supplementation of GPLC appears to provide
benefits that are dose dependent. While acute supple-
mentation of 4.5 grams was previously shown to provide
significant enhancement of anaerobic work capacity, the
present study suggests that chronic supplementation of
GPLC at 3.0 or 4.5 grams daily does not improve anae-
robic performance of repeated high speed high intensity
bouts and may actually produce detrimental effects with
high velocity, high intensity exercise. However, these
results also suggest that 1.5 g GPLC does provide
enhancement of anaerobic capacity. These findings also
suggest that long term supplementation with this dosage
(1.5 g/day) results in significantly lower lactate accumu-
lation with high intensity exercise.
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